CAR T cells show early promise in progressive multiple sclerosis

Heather Wood
Nature Reviews Neurology · Springer Nature · 2026-11-06 · DOI: 10.1038/s41582-026-01292-x

Аннотация

Nature Reviews Neurology, Published online: 06 November 2026; doi:10.1038/s41582-026-01292-x Phase I trial data presented at MSToronto2026 indicate that the chimeric antigen receptor (CAR) T cell therapy azercabtagene zapreleucel (azer-cel) is safe and has the potential to improve outcomes in people with progressive multiple sclerosis.

Читать у издателя →

Похожие статьи